SolarWindow (WNDW) 10-K 27 Nov 13 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Aug. 31, 2013	Nov. 20, 2013	Feb. 28, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'NEW ENERGY TECHNOLOGIES, INC.	'	'
Entity Central Index Key	'0001071840	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Aug-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--08-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$17,169,051
Entity Common Stock, Shares Outstanding	'	24,276,612	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Aug. 31, 2013	Aug. 31, 2012
ASSETS	'	'
Cash and cash equivalents	$347,493	$1,046,918
Deferred research and development costs	150,000	32,595
Prepaid expenses and other current assets	22,379	28,233
Total current assets	519,872	1,107,746
Equipment, net of accumulated depreciation of $12,025 and $5,882, respectively	13,823	19,966
Total assets	533,695	1,127,712
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable	122,356	63,403
Accrued liabilities	'	26,231
Convertible promissory note, net of discount of $0 and $999,485, respectively	'	515
Total current liabilities	122,356	90,149
Stockholders' equity	'	'
Preferred stock: $0.10 par value; 1,000,000 shares authorized, no shares issued and outstanding at August 31, 2013 and 2012, respectively.	'	'
Common stock: $0.001 par value; 300,000,000 shares authorized, 24,194,713 and 20,638,360 shares issued and outstanding at August 31, 2013 and 2012, respectively	24,194	20,638
Additional paid-in capital	17,441,034	13,798,282
Deficit accumulated during the development stage	-17,053,889	-12,781,357
Total stockholders' equity	411,339	1,037,563
Total liabilities and stockholders' equity	$533,695	$1,127,712

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Current assets	'	'
Equipment, accumulated depreciation	$12,025	$5,882
Current liabilities	'	'
Convertible promissory note, discount	$0	$999,485
Stockholders' equity	'	'
Preferred stock, par value	$0.10	$0.10
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	24,194,713	20,638,360
Common stock, shares outstanding	24,194,713	20,638,360

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		184 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Consolidated Statements Of Operations	'	'	'
Revenue	'	'	'
Operating expense	'	'	'
Selling, general and administrative	2,885,845	1,648,086	14,271,837
Research and development	356,877	672,443	2,947,016
Total operating expense	3,242,722	2,320,529	17,218,853
Loss from operations	-3,242,722	-2,320,529	-17,218,853
Other income (expense)	'	'	'
Interest income	'	'	98,582
Interest expense - other	-30,325	-26,231	-68,949
Interest expense - accretion of debt discount	-999,485	-515	-1,000,000
Loss on disposal of fixed assets	'	'	-5,307
Gain on dissolution of foreign subsidiary	'	'	59,704
Foreign exchange loss	'	-55	-86,428
Change in fair value of warrant liability	'	'	2,128,331
Payable written off	'	156,109	186,109
Total other income (expense)	-1,029,810	129,308	1,312,042
Loss from continuing operations	-4,272,532	-2,191,221	-15,906,811
Loss from discontinued operations	'	-242,210	-404,307
Net loss	($4,272,532)	($2,433,431)	($16,311,118)
Basic and Diluted Loss per Common Share:	'	'	'
Continuing operations	($0.19)	($0.11)	'
Discontinued operations	'	($0.01)	'
Total	($0.19)	($0.12)	'
Weighted average number of common shares outstanding - basic and diluted	22,686,892	20,638,360	'

Statement_Consolidated_Stateme

Statement - Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Common Stock	Additional Paid-In Capital	Deficit Accumulated During the Development Stage	Total
Beginning Balance, Amount at May. 04, 1998	'	'	'	'
Restricted common stock issued to related parties for management services at $0.001 per share, Amount	$3,000	'	'	$3,000
Restricted common stock issued to related parties for management services at $0.001 per share, Shares	3,000,000	'	'	'
Unrestricted common stock sales to third parties at $0.40 per share, Amount	375	149,625	'	150,000
Unrestricted common stock sales to third parties at $0.40 per share, Shares	375,000	'	'	'
Net loss	'	'	-12,326	-12,326
Ending Balance, Amount at Aug. 31, 1998	3,375	149,625	-12,326	140,674
Ending Balance, Shares at Aug. 31, 1998	3,375,000	'	'	'
Net loss	'	'	-77,946	-77,946
Ending Balance, Amount at Aug. 31, 1999	3,375	149,625	-90,272	62,728
Ending Balance, Shares at Aug. 31, 1999	3,375,000	'	'	'
Net loss	'	'	-12,446	-12,446
Ending Balance, Amount at Aug. 31, 2000	3,375	149,625	-102,718	50,282
Ending Balance, Shares at Aug. 31, 2000	3,375,000	'	'	'
Net loss	'	'	-12,904	-12,904
Ending Balance, Amount at Aug. 31, 2001	3,375	149,625	-115,622	37,378
Ending Balance, Shares at Aug. 31, 2001	3,375,000	'	'	'
Net loss	'	'	-54,935	-54,935
Ending Balance, Amount at Aug. 31, 2002	3,375	149,625	-170,557	-17,557
Beginning Balance, Shares at Aug. 31, 2002	3,375,000	'	'	'
Restricted common stock issued at $.001 per share to two related parties to satisfy outstanding management fees., Amount	10,333	92,999	'	103,332
Restricted common stock issued at $.001 per share to two related parties to satisfy outstanding management fees., Shares	10,333,200	'	'	'
Net loss	'	'	-97,662	-97,662
Ending Balance, Amount at Aug. 31, 2003	13,708	242,624	-268,219	-11,887
Ending Balance, Shares at Aug. 31, 2003	13,708,200	'	'	'
Net loss	'	'	-19,787	-19,787
Ending Balance, Amount at Aug. 31, 2004	13,708	242,624	-288,006	-31,674
Ending Balance, Shares at Aug. 31, 2004	13,708,200	'	'	'
Net loss	'	'	-103,142	-103,142
Ending Balance, Amount at Aug. 31, 2005	13,708	242,624	-391,148	-134,816
Beginning Balance, Shares at Aug. 31, 2005	13,708,200	'	'	'
Issuance of common stock and warrants at $0.50 per share, Amount	1,000	499,000	'	500,000
Issuance of common stock and warrants at $0.50 per share, Shares	1,000,000	'	'	'
Net loss	'	'	-157,982	-157,982
Ending Balance, Amount at Aug. 31, 2006	14,708	741,624	-549,130	207,202
Ending Balance, Shares at Aug. 31, 2006	14,708,200	'	'	'
Exercise of Class A Warrants at $0.50 per share, Amount	1,000	499,000	'	500,000
Exercise of Class A Warrants at $0.50 per share, Shares	1,000,000	'	'	'
Exercise of Class B Warrants at $0.55 per share, Amount	1,000	549,000	'	550,000
Exercise of Class B Warrants at $0.55 per share, Shares	1,000,000	'	'	'
Exercise of Class C Warrants at $1.50 per share, Amount	327	489,673	'	490,000
Exercise of Class C Warrants at $1.50 per share, Shares	326,667	'	'	'
Exercise of Class D Warrants at $1.65 per share, Amount	293	483,707	'	484,000
Exercise of Class D Warrants at $1.65 per share, Shares	293,333	'	'	'
Exercise of Class E Warrants at $1.80 per share, Amount	293	527,707	'	528,000
Exercise of Class E Warrants at $1.80 per share, Shares	293,333	'	'	'
Issuance of common stock and warrants at $1.50 per share, Amount	333	499,667	'	500,000
Issuance of common stock and warrants at $1.50 per share, Shares	333,333	'	'	'
Dividend paid - spin off of MircoChannel Technologies Corporation	'	'	-400,000	-400,000
Net loss	'	'	-1,442,769	-1,442,769
Ending Balance, Amount at Aug. 31, 2007	17,954	3,790,378	-2,391,899	1,416,433
Ending Balance, Shares at Aug. 31, 2007	17,954,866	'	'	'
Exercise of Class C Warrants at $1.50 per share, Amount	7	9,993	'	10,000
Exercise of Class C Warrants at $1.50 per share, Shares	6,667	'	'	'
Exercise of Class D Warrants at $1.65 per share, Amount	7	10,993	'	11,000
Exercise of Class D Warrants at $1.65 per share, Shares	6,667	'	'	'
Common stock and warrants issued for cash and services at $3.00 per Unit, Amount	1,225	3,394,730	'	3,395,955
Common stock and warrants issued for cash and services at $3.00 per Unit, Shares	1,225,000	'	'	'
Exercise of Class F Warrants at $3.75 per share, Amount	58	218,692	'	218,750
Exercise of Class F Warrants at $3.75 per share, Shares	58,333	'	'	'
Stock based compensation	'	3,600,303	'	3,600,303
Net loss	'	'	-5,721,545	-5,721,545
Ending Balance, Amount at Aug. 31, 2008	19,251	11,025,089	-8,113,444	2,930,896
Ending Balance, Shares at Aug. 31, 2008	19,251,533	'	'	'
Exercise of Class E Warrants at $1.80 per share, Amount	7	11,993	'	12,000
Exercise of Class E Warrants at $1.80 per share, Shares	6,667	'	'	'
Exercise of Class F Warrants at $3.75 per share, Amount	275	1,032,225	'	1,032,500
Exercise of Class F Warrants at $3.75 per share, Shares	275,333	'	'	'
Stock based compensation	'	183,312	'	183,312
Reversal of stock based compensation due to forfeiture of stock options	'	-3,591,093	'	-3,591,093
Net loss	'	'	1,961,175	1,961,175
Ending Balance, Amount at Aug. 31, 2009	19,533	8,661,526	-6,152,269	2,528,790
Ending Balance, Shares at Aug. 31, 2009	19,533,533	'	'	'
Stock based compensation	'	661,040	'	661,040
Reversal of stock based compensation due to forfeiture of stock options	'	-478,971	'	-478,971
Cumulative adjustment upon adoption of ASC 815-40	'	-1,785,560	-342,771	-2,128,331
Net loss	'	'	-233,136	-233,136
Ending Balance, Amount at Aug. 31, 2010	19,533	7,058,035	-6,728,176	349,392
Beginning Balance, Shares at Aug. 31, 2010	19,533,533	'	'	'
Exercise of Class F Warrants at $3.75 per share, Amount	1,055	3,953,320	'	3,954,375
Exercise of Class F Warrants at $3.75 per share, Shares	1,054,512	'	'	'
Stock based compensation	'	2,855,630	'	2,855,630
Reversal of stock based compensation due to forfeiture of stock options	'	-1,304,551	'	-1,304,551
Rounding due to reverse one for three stock split effective March 16, 2011, Amount	'	'	'	'
Rounding due to reverse one for three stock split effective March 16, 2011, Shares	-3	'	'	'
Exercise of stock options, Amount	50	30,750	'	30,800
Exercise of stock options, Shares	50,318	'	'	'
Net loss	'	'	-3,619,750	-3,619,750
Ending Balance, Amount at Aug. 31, 2011	20,638	12,593,184	-10,347,926	2,265,896
Ending Balance, Shares at Aug. 31, 2011	20,638,360	'	'	'
Stock based compensation	'	237,046	'	237,046
Reversal of stock based compensation due to forfeiture of stock options	'	-31,948	'	-31,948
Discount on convertible promissory note due to detachable warrants	'	547,050	'	547,050
Discount on convertible promissory note due to beneficial conversion feature	'	452,950	'	452,950
Net loss	'	'	-2,433,431	-2,433,431
Ending Balance, Amount at Aug. 31, 2012	20,638	13,798,282	-12,781,357	1,037,563
Beginning Balance, Shares at Aug. 31, 2012	20,638,360	'	'	'
Stock based compensation	'	334,305	'	324,230
Reversal of stock based compensation due to forfeiture of stock options	'	-10,075	'	-10,075
Exercise of stock options, Amount	22	-22	'	'
Exercise of stock options, Shares	22,672	'	'	'
Issuance of common stock and warrants at $0.64 per unit, Amount	1,875	1,198,125	'	1,200,000
Issuance of common stock and warrants at $0.64 per unit, Shares	1,875,000	'	'	'
Issuance of common stock upon the conversion of note at $0.64 per share, Amount	1,651	1,054,905	'	1,056,556
Issuance of common stock upon the conversion of note at $0.64 per share, Shares	1,650,869	'	'	'
Issuance of common stock upon the exercise of Series H Warrants, Amount	8	6,476	'	6,484
Issuance of common stock upon the exercise of Series H Warrants, Shares	7,812	'	'	'
Expense related to issuance of Series H Warrants as inducement to convert April 17, 2012, $1,000,000 note	'	1,059,038	'	1,059,038
Net loss	'	'	-4,272,532	-4,272,532
Ending Balance, Amount at Aug. 31, 2013	$24,194	$17,441,034	($17,053,889)	$411,339
Ending Balance, Shares at Aug. 31, 2013	24,194,713	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		184 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Cash flows from operating activities	'	'	'
Loss from continuing operations	($4,272,532)	($2,191,221)	($15,906,811)
Add: loss from discontinued operations	'	-242,210	-404,307
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation	6,143	5,419	16,507
Stock based compensation expense	324,230	237,046	7,871,637
Reversal of stock based compensation expense due to forfeiture of stock options	-10,075	-31,948	-5,416,638
Warrants issued to note holder	1,059,038	'	1,059,038
Change in fair value of warrant liability	'	'	-2,128,331
Loss on disposal of fixed assets	'	'	5,307
Payable written off	'	-156,109	-186,109
Common stock issued for services	'	'	3,000
Common stock issued for debt settlement	'	'	-103,332
Accretion of debt discount	999,485	515	1,000,000
Changes in operating assets and liabilities:	'	'	'
Decrease (increase) in deferred research and development costs	-117,405	123,684	-150,000
Decrease (increase) in prepaid expenses and other current assets	5,854	41,149	-22,379
Increase (decrease) in accounts payable	58,953	-56,465	152,356
Increase (decrease) in accrued liabilities	30,325	21,331	212,665
Net cash used in operating activities	-1,905,909	-2,248,809	-13,790,733
Cash flows from investing activity	'	'	'
Purchase of equipment	'	-24,458	-35,637
Net cash used in investing activity	'	-24,458	-35,637
Cash flows from financing activities	'	'	'
Proceeds from the issuance of common stock, exercise of warrants and stock options, net	1,206,484	'	13,573,863
Repayment of promissory note	'	'	-155,000
Proceeds from promissory notes	'	1,000,000	1,155,000
Dividend paid	'	'	-400,000
Net cash provided by financing activities	1,206,484	1,000,000	14,173,863
Increase (decrease) in cash and cash equivalents	-699,425	-1,273,267	347,493
Cash and cash equivalents at beginning of period	1,046,918	2,320,185	'
Cash and cash equivalents at end of period	347,493	1,046,918	347,493
Supplemental disclosure of cash flow information:	'	'	'
Interest paid in cash	'	'	12,393
Income taxes paid in cash	'	'	'
Supplemental disclosure of non-cash transactions:	'	'	'
Accrued management fees converted to equity	'	'	103,332
Debt discount recorded for value of warrants issued	'	547,050	547,050
Debt discount recorded for beneficial conversion feature	'	452,950	452,950
Warrants issued for broker commissions	'	'	642,980
Common stock issued for conversion of note payable	$1,056,556	'	$1,056,556

Organization_Liquidity_and_Sum

Organization, Liquidity and Summary of Significant Accounting Policies	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 1 - Organization, Liquidity and Summary of Significant Accounting Policies	'
	Organization
	New Energy Technologies, Inc. (the “Company”, "we", "us", "our") was incorporated in the State of Nevada on May 5, 1998, under the name “Octillion Corp.” On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Sungen Energy, Inc. (“Sungen”), Kinetic Energy Corporation (“KEC”), and New Energy Solar Corporation (“New Energy Solar”).
	Sungen was incorporated on July 11, 2006, in the State of Nevada and is currently inactive.
	KEC was incorporated on June 19, 2008, in the State of Nevada and holds the patents related to the Company’s MotionPower™ technology. The Company’s business activities related to the MotionPower™ technology are conducted through KEC.
	New Energy Solar was incorporated on February 9, 2009, in the State of Florida and has entered into agreements with USF to sponsor research related to the Company’s SolarWindow™ technology.
	On March 16, 2011, pursuant to a consent signed by the Company’s shareholders owning a majority of the Company’s then issued and outstanding shares of common stock, the Company filed a Certificate of Amendment to its Certificate of Incorporation increasing its authorized shares of common stock, $0.001 par value, from 100,000,000 to 300,000,000.
	On August 19, 2011, the Company established Nakoda Energy, Inc. (“Nakoda”), a California corporation and wholly owned subsidiary of the Company, which began operations in September 2011. Due to the high costs associated with growing operations and difficult financing environment, management suspended all Nakoda related operations as of November 30, 2011. On January 20, 2012, management completed the sale of Nakoda pursuant to a stock purchase agreement. The Company did not recognize any revenue from Nakoda related operations nor were there any recorded assets or liabilities as of and during the periods presented.
	The Company is a renewable and alternative energy company, actively developing two novel technologies for generating sustainable electricity, one of which collects light energy from the sun and artificial sources (SolarWindow™), and the other harvests kinetic energy present in moving vehicles (MotionPower™). The Company’s proprietary, patent-pending technologies and products, which are the subjects of one hundred and one (101) patent-filings, have been invented, designed, engineered, and prototyped in preparation for further field testing, product development, and eventual commercial deployment.
	The Company’s SolarWindow™ technology generates electrical energy when the electricity-generating coating is applied to glass and plastic surfaces creating semi-transparent, see-through solar cells. If successfully developed, SolarWindow™ could potentially be used on any of the more than 85 million commercial and residential buildings in the United States alone (U.S. Census Bureau, 2007 American Housing Survey & U.S. Energy Information Administration, 2003 Commercial Buildings Energy Consumption Survey). The Company’s SolarWindow™ technology is the subject of forty-two (42) patent filings.
	The Company’s MotionPower™ technology harvests, or captures, the “kinetic” or “motion” energy of cars, trucks, buses, and heavy commercial vehicles when they pass over the system or slow down before coming to a stop. MotionPower™ converts this captured energy into electricity. If successfully developed, MotionPower™ could potentially be used to harvest kinetic energy generated by any of the estimated 250 million vehicles registered in America (U.S. Department of Transportation Federal Highway Administration, 2008 Highway Statistics), which drive approximately six billion miles on our nation’s roadways every day (U.S. Environmental Protection Agency). The Company’s MotionPower™ technology is the subject of fifty-nine (59) patent filings.
	The Company’s product development programs involve ongoing research and development efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by its contract engineers, scientists, and consultants.
	The Company continues to assess the ongoing development and value propositions of its novel SolarWindow™ and MotionPower™ technologies. This assessment helps us strategically focus on specific technology development which best delivers significant long-term commercial competitive advantages.
	Liquidity
	The Company is a development stage company, does not have any commercialized products and has not generated any revenue since inception. The Company has an accumulated deficit of $17,053,889 as of August 31, 2013, and does not have positive cash flows from operating activities. Included in the deficit are non cash expenses totaling $4,620,369 relating to the issuance of stock for services, compensatory stock options, warrants granted for value and accretion of debt discount. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.
	On February 1, 2013, the Company received $1,200,000 from an equity financing through the sale of its securities. As of August 31, 2013, the Company had cash and cash equivalents of $347,493. Subsequent to the Company’s fiscal year end, on October 7, 2013, the Company received proceeds of $3,000,000 in connection with issuing a 7% unsecured convertible note. Based upon its current and near term anticipated level of operations and expenditures, the Company believes that cash on hand should be sufficient to enable it to continue operations into our fiscal year ended August 31, 2015. However, there is no assurance that the Company will be able to generate revenue and achieve profitability or secure additional financing once the current cash balance is depleted.
	If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company’s business, operating results, financial condition and prospects. In particular, the Company may be required to delay, reduce the scope of or terminate one or more of its research programs, sell rights to its SolarWindow™ technology and/or MotionPowerTM technology or other technologies or products based upon such technologies, or license the rights to such technologies or products on terms that are less favorable to the Company than might otherwise be available.
	Summary of Significant Accounting Policies
	Principles of Consolidation
	These consolidated financial statements presented are those of the Company and its wholly owned subsidiaries, Sungen, KEC, and New Energy Solar. All significant intercompany balances and transactions have been eliminated.
	Estimates
	The preparation of the Company’s consolidated financial statements requires management to make estimates and use assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. On an on-going basis, the Company evaluates its estimates. Actual results and outcomes may differ materially from these estimates and assumptions.
	Cash and Cash Equivalents
	Cash and cash equivalents includes highly liquid investments with original maturities of three months or less. The Company has amounts deposited with financial institutions in excess of federally insured limits.
	Fair Value Measurement
	The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value:
	Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. The Company has no assets or liabilities valued with Level 1 inputs.
	Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. The Company has no assets or liabilities valued with Level 2 inputs.
	Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level 3 inputs.
	Fair Value of Financial Instruments
	The carrying value of cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of our notes payable due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.
	Research and Development
	Research and development costs represent costs incurred to develop the Company’s technology, including salaries and benefits for research and development personnel, allocated overhead and facility occupancy costs, supplies, equipment purchase and repair and other costs. Research and development costs are expensed when incurred, except for nonrefundable advance payments for future research and development activities which are capitalized and recognized as expense as the related services are performed.
	Stock-Based Compensation
	The Company measures all employee stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes-Merton formula to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes-Merton formula requires management to make assumptions regarding the option lives, expected volatility, and risk free interest rates. See “Note 4 - Stockholders’ Equity (Deficit)” and “Note 5 - Stock Options” for additional information on the Company’s stock-based compensation plans.
	Income Taxes
	The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.
	Segment Reporting
	The Company’s business is considered to be operating in one segment based upon the Company’s organizational structure, the way in which the operations are managed and evaluated, the availability of separate financial results and materiality considerations.
	Net Income (Loss) Per Share
	The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The computation of diluted net income per share does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on earnings per share. Therefore, when calculating EPS if the Company experienced a loss, there is no inclusion of dilutive securities as their inclusion in the EPS calculation is antidilutive. Furthermore, options and warrants will have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options or warrants (they are in the money). See “Note 6 - Net Loss Per Share” for further discussion.
	All share and per share amounts reflect the 1-for-3 reverse stock split declared effective on March 21, 2011, by FINRA.
	Recently Adopted Accounting Pronouncements
	The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable to the Company, it has not identified any standards that it believes merit further discussion. The Company believes that none of the new standards will have a significant impact on its consolidated financial statements.

Accounts_Payable

Accounts Payable	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 2 - Accounts Payable	'
	At August 31, 2013, accounts payable totaling $122,356 consisted of $42,539 of professional services, $70,327 related to R&D and $9,490 of trade payables.
	At August 31, 2012, accounts payable totaling $63,403 consisted of $24,863 of professional services and $38,540 of trade payables. Accrued liabilities consisted of $26,231 of accrued interest on the Company’s $1,000,000 outstanding Bridge Loan dated April 17, 2012.

Convertible_Promissory_Note

Convertible Promissory Note	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 3 - Convertible Promissory Note	'
	On April 17, 2012, the Company entered into a Bridge Loan Agreement (the “Loan Agreement”) with 1420524 Alberta Ltd. (the “Creditor”), pursuant to which the Company borrowed $1,000,000 at an annual interest rate of 7% (the “Loan”). As a condition to the Creditor’s entry into the Loan Agreement, the Company issued the Creditor a Series G Stock Purchase Warrant to purchase 625,000 shares of the Company’s common stock (the “Series G Warrant”), which is exercisable through April 17, 2015, with an initial exercise price of 84% of the average of the closing price for our common stock as reported on the OTC Markets Group Inc. QB tier (the “OTCQB”) for the five trading days immediately preceding the closing of the Loan, or $1.92 per share, subject to adjustment as provided therein. According to the original terms of the Loan Agreement, the Creditor could elect, in its sole discretion, to convert all or any portion of the outstanding principal amount of the Loan, and any or all accrued and unpaid interest thereon into shares of our common stock at an initial fixed conversion price equal to seventy (70%) percent of the average of the closing price for the Company’s common stock as reported on the OTCQB for the five trading days immediately preceding the closing of the Loan, or $1.60 per share subject to adjustment as provided therein. The debt discount attributable to the relative fair value of the warrants and the beneficial conversion feature amounted to $547,050 and $452,950, respectively, and was to be accreted over the term of the Loan using the effective interest method.
	On February 1, 2013, the Company and the Creditor entered into a Loan Conversion Agreement (“LCA”) whereby the Creditor agreed to convert the entire balance outstanding, including $1,000,000 of principal and $56,556 of accrued interest payable into 1,650,869 shares of restricted common stock. In order to induce the Creditor to convert the Loan into shares of common stock, and eliminate the Company’s obligation to repay the Loan in cash, the effective conversion price was reduced to $0.64 (the price at which the Company sold shares pursuant to its self-directed registered offering; see “NOTE 4 – Stockholders’ Equity (Deficit)” below) from the initial conversion price of $1.60. In addition, as part of the conversion, the Company issued to the Creditor a Series H Warrant to purchase 825,435 shares of the Company’s common stock (See “NOTE 4 – Stockholders’ Equity (Deficit)” below for additional information). No incremental expense was recognized in these consolidated financial statements related to the reduction in the exercise price of the Series G Warrant, and the conversion of the Loan, because the transaction did not meet the requirements for an inducement under accounting principles generally accepted in the United States. As such, the Loan conversion was accounted for as a debt extinguishment with no gain or loss recognized due to the related party nature of the transaction. The Company recognized expense amounting to $1,059,038 for the issuance of the Series H Warrant to the Creditor, representing additional financing costs associated with the Loan.
	During the years ended August 31, 2013 and 2012, the Company recognized $30,325 and $26,231, respectively of interest expense related to the Loan and $999,485 and $515, respectively of accretion related to the debt discount. As a result of the Loan conversion, the debt discount was fully amortized by February 1, 2013, the date of the LCA.

Stockholders_Equity_Deficit

Stockholders' Equity (Deficit)	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 4 - Stockholders' Equity (Deficit)	'
	On February 1, 2013, in full satisfaction of the 2012 Promissory Note, the Company issued to the Creditor 1,650,869 shares of restricted common stock upon the conversion of the 2012 Promissory Note, as adjusted in accordance with the terms of the LCA. Additionally, pursuant to the terms of the LCA, the Company issued to the Creditor 825,435 Series H Warrants and reduced the exercise price of the Series G Warrant to $0.64 (See “Note 3 - Convertible Promissory Note” above for additional information).
	On February 1, 2013, the Company completed a self-directed registered offering of 1,875,000 units at a price of $0.64 per unit for $1,200,000 in aggregate proceeds (the “Registered Offering”). Each unit consisted of one share of the Company’s common stock and one-half Series H Stock Purchase Warrant (“Series H Warrant”) to purchase one-half of a share of common stock at the initial exercise price of $0.83 per share for a period of three years from the date of issuance. The Company issued 937,503 Series H Warrants as part of the Registered Offering. The relative fair value of the common stock was estimated to be $638,717 and the relative fair value of the warrants was estimated to be $561,283 as determined based on the relative fair value allocation of the proceeds received. The Series H Warrants were valued using the Black-Scholes option pricing model using the following variables: $0.83 exercise price, $1.48 stock price, 161% volatility, 0.40% risk-free interest rate, 3 year term and no dividends.
	On March 21, 2013, the Company issued 7,812 shares of common stock upon the exercise of an equal number of Series H Warrants and received proceeds of $6,484.
	Warrants
	Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. A summary of the Company’s warrants outstanding and exercisable as of August 31, 2013 and 2012 is as follows:
		Shares of Common Stock Issuable from Warrants Outstanding as of
	Description	31-Aug-13		31-Aug-12		Exercise Price		Expiration
	Series G		625,000		625,000	$	0.64	17-Apr-15
	Series H		1,755,126		-	$	0.83	1-Feb-16
	Total		2,380,126		625,000
	The Series G Warrant was issued on April 17, 2012, as a condition to the Creditor entering into the Loan Agreement more fully described above under “Note 3 - Convertible Promissory Note.” In order to induce the Creditor to convert the Loan into shares of the Company’s common stock, the initial exercise price of $1.92 was reduced to $0.64. Additionally, the Series G Warrant contains a cashless exercise provision and registration rights requiring us to file a registration statement with the SEC for the shares issuable upon exercise of the Series G Warrant within 60 days receipt of a written request by the Creditor.
	As inducement to convert the Loan, on February 1, 2013, the Company issued to the Creditor 825,435 Series H Warrants (See “Note 3 - Convertible Promissory Note” above for additional information). The warrants have an exercise price of $0.83 per share, expire on the third anniversary of the LCA, or on February 1, 2016 and may be exercised in whole or in part at any time from the date of issuance through expiration. Based on the following Black-Scholes Option Pricing Model assumptions: exercise price - $0.83; market price of common stock - $1.48 per share; estimated volatility - 161%; risk free interest rate - 0.40%; expected dividend rate - 0%; and expected life - 3.0 years, the Company calculated the fair value of these warrants to be $1,059,038.
	On February 1, 2013, as part of the Registered Offering, the Company issued 937,503 Series H Warrants (See “Note 4 – Stockholders’ Equity (Deficit)” above for additional information).
	During the year ended August 31, 2013, the Company received $6,484 upon the exercise of 7,812 Series H Warrants by two warrant holders.

Stock_Options

Stock Options	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 5 - Stock Options	'
	On October 10, 2006, the Company’s Board of Directors (the “Board”) adopted and approved the 2006 Incentive Stock Option Plan (the “2006 Plan”) that provides for the grant of stock options to employees, directors, officers and consultants. Stock option grants vest over two to five years and expire ten years after the date of grant. Stockholders previously approved 5,000,000 shares for grant under the 2006 Plan, of which 3,892,495 remain available for grant and 136,667 options have been exercised as of August 31, 2013. All shares approved for grant and subsequently forfeited are available for future grant. The Company does not repurchase shares to fulfill the requirements of options that are exercised. The Company issues new shares when options are exercised.
	The Company measures all stock-based compensation based on the fair value on the grant date using the Black-Scholes-Merton formula and recognizes expense over the requisite service period. The Black-Scholes model requires management to make assumptions regarding option time to expiration, expected volatility, and risk-free interest rates, all of which have a significant impact on the fair value of the option.
	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a bond with a similar term. The Company does not anticipate declaring dividends in the foreseeable future. Volatility is calculated based on the historical closing stock prices. The Company uses the “simplified” method for determining the expected term of its “plain vanilla” stock options. The Company recognizes compensation expense for only the portion of stock options that are expected to vest. Therefore, the Company applies an estimated forfeiture rate that is derived from historical employee termination data and adjusted for expected future employee turnover rates. If the actual number of forfeitures differs from those estimated by the Company, additional adjustments to compensation expense may be required in future periods.
	A summary of the Company’s stock option activity for the year ended August 31, 2013, and related information follows:
			Number of Options				Weighted Average Exercise Price ($)			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value ($)
	Outstanding at August 31, 2012			861,671				2.1
	Grants			177,500				1.59
	Exercises			(63,333	)			1.65
	Forfeitures			(5,000	)			3.27
	Outstanding at August 31, 2013			970,838				2.03		6.83 years		$	236,334
	Exercisable at August 31, 2013			479,337				2.42		6.27 years		$	108,084
	Available for grant at August 31, 2013			3,892,495
	The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all “in-the-money” options (i.e. the difference between the Company’s closing stock price on the last trading day of the period covered by this report and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all in-the-money option holders exercised their options on August 31, 2013. The intrinsic value of the option changes based upon the fair market value of the Company’s common stock. Since the closing stock price was $1.90 on August 31, 2013 and 828,335 outstanding options have an exercise price below $1.90 per share, as of August 31, 2013, there is intrinsic value to our outstanding in-the-money stock options.
	The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Consolidated Statements of Operations for the years ended August 31, 2013 and 2012, and from May 5, 1998 (inception) to August 31, 2013:
			Year Ended August 31,								Cumulative
											5-May-98
											(Inception) to
											August 31,
			2013				2012				2013
	Stock Compensation Expense:
	Selling general and administrative expense		$	324,230			$	205,098			$	2,454,998
	As of August 31, 2013, the Company had $67,329 of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a period of 2.0 years.
	Stock Option Activity During the Year Ended August 31, 2013
	On December 20, 2012, the Company granted two stock options to purchase up to 15,000 (a 10,000 and 5,000 option grant, respectively) shares of the Company’s common stock at an exercise price of $0.80 per share, the fair market value of the Company’s common stock on the date of grant, to two employees as partial compensation for services. The stock options expire ten years from the date of grant, on December 20, 2022 and vest as follows: (a) 7,500 shares vest immediately on the date of grant and (b) 7,500 shares on the one-year anniversary on December 20, 2013. The stock options are further subject to the terms and conditions of a stock option agreement between the Company and the employees. Under the terms of the stock option agreement, the stock option agreement will terminate and there will be no further vesting of stock options effective as of the date that employees cease to be one of the Company’s employees. Upon termination of such service, the employee will have a specified period of time to exercise vested stock options, if any. The grant date fair value of the stock option granted was $11,700, or $0.78 per option, estimated using the Black-Scholes model containing the following assumptions: Exercise price / spot price of $0.80 per share, dividend yield of 0%, volatility of 160.1%, risk-free rate of 1.14%, and a term of 7.67 years. During the year ended August 31, 2013, the Company recognized $10,238 of expense related to these two issuances.
	On April 27, 2012, pursuant to his employment agreement, the Company’s former Vice President of Business and Technology Development, Mr. John Patrick Thompson received a grant of 100,000 stock options. The options have an exercise price of $2.30, the fair market value of the Company’s common stock on the date of grant. The stock options expire ten years from the date of grant, on April 27, 2022 and vest in various amounts upon the meeting of certain milestones and which vesting is subject to Board approval. The stock option is further subject to the terms and conditions of a stock option agreement between the Company and the employee. Under the terms of the stock option agreement, the stock option agreement will terminate and there will be no further vesting of stock options effective as of the date the employee ceases to be one of the Company’s employees. Upon termination of such service, the employee will have a specified period of time to exercise vested stock options, if any. The grant date fair value of the stock option granted was $225,000, or $2.25 per option, estimated using the Black-Scholes model containing the following assumptions: Exercise price / spot price of $2.30 per share, dividend yield of 0%, volatility of 167.1%, risk-free rate of 1.34%, and term of 7.67 years. The Company recognizes compensation cost associated with this stock option grant with performance conditions when the Company determines that it is probable that certain milestones will be achieved. On December 20, 2012, the Company’s Board determined that milestones related to 2,500 options were substantially met. Thus, during the year ended August 31, 2013, the Company recognized $5,625 of expense related to this award. On August 6, 2013, Mr. Thompson's employment with the Company ceased. As a result no further vesting of the aforementioned option grant will vest. Mr. Thompson has 120 days from the date of his departure to exercise his 2,500 vested options.
	On January 23, 2013, the Board approved, and the Company granted, a stock option to each of the Company’s four directors, including John Conklin, CEO, to purchase 40,000 shares of its common stock at an exercise price of $1.65 per share, the fair market value of the Company’s common stock on the date of grant. Each stock option expires ten years from the date the applicable stock option agreement was executed, on January 23, 2023, and vests as follows: (a) 20,000 shares vest immediately on the date of grant and (b) 20,000 shares on the one-year anniversary on January 23, 2014. The stock options are further subject to the terms and conditions of a stock option agreement between the Company and each director. Under the terms of the stock option agreement, the stock option agreement will terminate and there will be no further vesting of stock options effective as of the date that the director ceases to be one of the Company’s directors. Upon termination of such service, the director will have a specified period of time to exercise vested stock options, if any. The grant date fair value of each of the stock options granted to each of the Company’s directors was $64,386 estimated using a Black-Scholes model containing the following assumptions: Exercise price / spot price of $1.65 per share, dividend yield of 0%, volatility of 161.1%, risk-free rate of 1.24%, and a term of 7.67 years. During the year ended August 31, 2013, the Company recognized $225,349 of expense related to these four issuances.
	On December 10, 2012, Mr. Peter Fusaro resigned from the Board. As a result of his resignation, Mr. Fusaro forfeited 5,000 unvested stock options and had vested 11,667 stock options. Total stock based compensation expense related to Mr. Fusaro’s options was $48,850 of which $44,270 was expensed through August 31, 2012. On November 30, 2012, the Company reversed $10,075 of expense related to forfeited options on which expense was previously recorded resulting in total recognized expense related to Mr. Fusaro’s options of $34,195. Mr. Fusaro has until December 10, 2014, to exercise his 11,667 vested stock options.
	In addition to the above, the Company recorded compensation expense of $88,644 during the year ended August 31, 2013 related to options granted prior to 2012 and which are currently vesting.
	Stock Option Activity During the Year Ended August 31, 2012
	On December 8, 2011, Mr. Todd Pitcher resigned from the Board. Mr. Pitcher had vested 6,667 stock options and forfeited 10,000 unvested stock options with an exercise price of $3.27 per share. During the year ended August 31, 2011, the Company recorded stock based compensation of $27,784 for the amortization of the fair value of his stock option. Since the stock option was forfeited prior to 10,000 options vesting, $8,243 previously recognized for stock based compensation was reversed on November 30, 2011, resulting in total stock based compensation expense related to Mr. Pitcher’s stock option grant of $19,541. Mr. Pitcher has until December 8, 2013, to exercise his 6,667 vested stock options.
	On August 12, 2012, 83,334 vested options with an exercise price of $6.21 per share held by Mr. Andrew Farago, the Company’s former Chief Operating Officer expired unexercised.
	On September 30, 2012, Mr. Javier Jimenez resigned from the Board. As a result of his resignation, Mr. Jimenez forfeited 5,000 unvested stock options and had vested 11,667 stock options with an exercise price of $3.27 per share. The Company recorded stock based compensation totaling $91,780 related to the amortization of the fair value of this stock option grant, including the recognition of $66,252 of expense for the year ended August 31, 2012. Since the stock option was forfeited prior to 5,000 options vesting, $23,705 previously recognized for stock based compensation was reversed on August 31, 2012, resulting in total stock based compensation expense related to Mr. Jimenez’s stock option grant of $68,075. Mr. Jimenez has until September 30, 2014, to exercise his 11,667 vested stock options.
	The following table summarizes information about stock options outstanding and exercisable at August 31, 2013:
					Stock Options Outstanding										Stock Options Exercisable
	Range of				Number of				Weighted				Weighted		Number		Weighted Average		Weighted
	Exercise				Options				Average				Average		of Options		Remaining		Average
	Prices				Outstanding				Contractual				Exercise		Exercisable		Contractual		Exercise
									Life (years)				Price				Life (Years)		Price
	$	0.8				15,000				9.31			$	0.8		7,500		9.31	$	0.8
		1.32				50,001				1.29				1.32		50,001		1.29		1.32
		1.65				763,334				6.83				1.65		283,333		8.34		1.65
		2.3				2,500				8.66				2.3		2,500		8.66		2.3
		2.5				10,000				7.6				2.5		6,000		7.6		2.5
		2.55				33,334				5.03				2.55		33,334		5.03		2.55
		3.27				18,334				0.91				3.27		18,334		0.91		3.27
		4.98				16,667				4.53				4.98		16,667		4.53		4.98
		5.94				50,001				7.32				5.94		50,001		7.32		5.94
		6.51				11,667				1.08				6.51		11,667		1.08		6.51
	Total					970,838				6.83			$	2.03		479,337		6.27	$	2.42

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 6 - Net Loss Per Share	'
	During the years ended August 31, 2013 and 2012, the Company recorded a net loss. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share for the past two fiscal years because to do so would be antidilutive.
	Following is the computation of basic and diluted net loss per share for the years ended August 31, 2013 and 2012:
		Year Ended
		August 31,
		2013			2012
	Basic and Diluted EPS Computation
	Numerator:
	Loss available to common stockholders'	$	(4,272,532	)	$	(2,433,431	)
	Denominator:
	Weighted average number of common shares outstanding		22,686,892			20,638,360
	Basic and diluted EPS	$	(0.19	)	$	(0.12	)

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 7 - Related Party Transactions	'
	A related party is generally defined as (i) any person that holds 10% or more of the Company’s securities and their immediate families, (ii) the Company’s management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
	For services rendered in the capacity of a Board member, non-employee Board members received $3,750 per quarter through the quarter ended February 28, 2013. The amount was increased to $4,250 per quarter beginning with our third quarter ending on May 31, 2013. New Board member compensation is pro rated in their first quarter. During the years ended August 31, 2013 and 2012, the Company incurred $59,618 and $91,200, respectively in cash based Board compensation. Additionally, the Company recognized stock compensation expense related to stock options granted for services rendered by non-employee directors of the Company, which is included in professional fees (See “Note 5 - Stock Options” above) during the years ended August 31, 2013 and 2012 of $176,699 and $90,297, respectively.
	During his tenure as Director from March 21, 2011 through December 11, 2012, Mr. Peter Fusaro provided consulting services to the Company. In addition to the quarterly Board fees received as discussed above, during the year ended August 31, 2013 and 2012, the Company paid Mr. Fusaro $2,100 and $13,300, respectively.
	The law firm of Sierchio & Company, LLP, of which Joseph Sierchio, one of the Company’s directors, is a principal, has provided counsel to the Company since its inception. In July 2008, the Company asked Mr. Sierchio to join the Company’s Board. During the years ended August 31, 2013 and 2012, the law firm of Sierchio & Company, LLP provided $128,924 and $176,404, respectively, of legal services. At August 31, 2013, the Company owed Sierchio & Company, LLP $38,013 which is included in accounts payable.
	On February 1, 2013, Kalen Capital Holdings LLC, a wholly owned subsidiary of Kalen Capital Corporation, a shareholder owning in excess of 5% of the Company’s issued and outstanding stock, purchased 1,843,750 shares of the Company’s common stock and a Series H Warrant to purchase 921,875 shares of the Company’s common stock for an aggregate purchase price of $1,180,000 pursuant to the registered public offering conducted by the Company (See “NOTE 4 – Stockholders’ Equity (Deficit)” above).
	All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.

Income_Taxes

Income Taxes	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 8 - Income Taxes	'
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets at August 31, 2013 and 2012 are as follows:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	3,404,418		$	2,506,712
	Capitalized research and development		836,568			756,562
	Depreciation		(4,700	)		(6,788	)
	Stock based compensation		1,130,104			659,793
	Research and development credit carry forward		206,715			174,558
	Total deferred tax assets		5,573,105			4,090,837
	Less: valuation allowance		(5,573,105	)		(4,090,837	)
	Net deferred tax asset	$	-		$	-
	The net increase in the valuation allowance for deferred tax assets was $1,482,268 and $869,333 for the years ended August 31, 2013 and 2012, respectively. The Company evaluates its valuation allowance requirements on an annual basis based on projected future operations. When circumstances change and this causes a change in management’s judgment about the realizability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current operations.
	For federal income tax purposes, the Company has net U.S. operating loss carry forwards at August 31, 2013 available to offset future federal taxable income, if any, of $10,012,994, which will fully expire by the fiscal year ended August 31, 2033. Accordingly, there is no current tax expense for the years ended August 31, 2013 and 2012. In addition, the Company has research and development tax credit carry forwards of $206,715 at August 31, 2013, which are available to offset federal income taxes and begin to expire during the year ended August 31, 2026.
	The utilization of the tax net operating loss carry forwards may be limited due to ownership changes that have occurred as a result of sales of common stock.
	The effects of state income taxes were insignificant for the years ended August 31, 2013 and 2012.
	The following is a reconciliation between expected income tax benefit and actual, using the applicable statutory income tax rate of 34% for the years ended August 31, 2013 and 2012:
		2013			2012
	Income tax benefit at statutory rate	$	1,452,661		$	827,367
	Non-deductible meals and entertainment		(2,550	)		(1,280	)
	Research and development credit		32,157			53,576
	Other		-			(10,330	)
	Change in valuation allowance		(1,482,268	)		(869,333	)
		$	-		$	-
	The fiscal years 2009 through 2013 remain open to examination by federal authorities and other jurisdictions in which the Company operates.

Subsequent_Events

Subsequent Events	12 Months Ended
	Aug. 31, 2013
Notes to Financial Statements	'
Note 9 - Subsequent Events	'
	On October 31, 2013, Mr. Jatinder S. Bhogal resigned as a director.
	On October 7, 2013, the Company received proceeds of $3,000,000 in connection with issuing a 7% unsecured convertible note (the “Note”) to Kalen Capital Corporation, a private corporation owning in excess of 10% of the Company’s issued and outstanding shares of common stock. As part of the loan the Company issued a Series I Stock Purchase Warrant (the “Series I Warrant”) allowing the holder to purchase up to 921,875 shares of the Company’s common stock at an initial exercise price of $1.37 for a period on five (5) years. The Series I Warrant is exercisable on a “cashless basis.” The Note is due on October 6, 2014, and interest is to be compounded quarterly. The conversion price of the Note is the lesser of (1) $1.37, or (2) 70% of the 20 day average closing price of the common stock. The Note is convertible into units, with each unit consisting of (a) one share of common stock; (b) one Series J Stock Purchase Warrant for the purchase of one share of common stock; and (c) one Series J Stock Purchase Warrant for the purchase of one share of common stock. For additional information regarding the Note see the Company’s Current Report on Form 8-K filed by the Company with the SEC on October 10, 2013.

Organization_Going_Concern_and

Organization, Going Concern and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2013
Organization Going Concern And Summary Of Significant Accounting Policies Policies	'
Organization	'
	New Energy Technologies, Inc. (the “Company”, "we", "us", "our") was incorporated in the State of Nevada on May 5, 1998, under the name “Octillion Corp.” On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Sungen Energy, Inc. (“Sungen”), Kinetic Energy Corporation (“KEC”), and New Energy Solar Corporation (“New Energy Solar”).
	Sungen was incorporated on July 11, 2006, in the State of Nevada and is currently inactive.
	KEC was incorporated on June 19, 2008, in the State of Nevada and holds the patents related to the Company’s MotionPower™ technology. The Company’s business activities related to the MotionPower™ technology are conducted through KEC.
	New Energy Solar was incorporated on February 9, 2009, in the State of Florida and has entered into agreements with USF to sponsor research related to the Company’s SolarWindow™ technology.
	On March 16, 2011, pursuant to a consent signed by the Company’s shareholders owning a majority of the Company’s then issued and outstanding shares of common stock, the Company filed a Certificate of Amendment to its Certificate of Incorporation increasing its authorized shares of common stock, $0.001 par value, from 100,000,000 to 300,000,000.
	On August 19, 2011, the Company established Nakoda Energy, Inc. (“Nakoda”), a California corporation and wholly owned subsidiary of the Company, which began operations in September 2011. Due to the high costs associated with growing operations and difficult financing environment, management suspended all Nakoda related operations as of November 30, 2011. On January 20, 2012, management completed the sale of Nakoda pursuant to a stock purchase agreement. The Company did not recognize any revenue from Nakoda related operations nor were there any recorded assets or liabilities as of and during the periods presented.
	The Company is a renewable and alternative energy company, actively developing two novel technologies for generating sustainable electricity, one of which collects light energy from the sun and artificial sources (SolarWindow™), and the other harvests kinetic energy present in moving vehicles (MotionPower™). The Company’s proprietary, patent-pending technologies and products, which are the subjects of one hundred and one (101) patent-filings, have been invented, designed, engineered, and prototyped in preparation for further field testing, product development, and eventual commercial deployment.
	The Company’s SolarWindow™ technology generates electrical energy when the electricity-generating coating is applied to glass and plastic surfaces creating semi-transparent, see-through solar cells. If successfully developed, SolarWindow™ could potentially be used on any of the more than 85 million commercial and residential buildings in the United States alone (U.S. Census Bureau, 2007 American Housing Survey & U.S. Energy Information Administration, 2003 Commercial Buildings Energy Consumption Survey). The Company’s SolarWindow™ technology is the subject of forty-two (42) patent filings.
	The Company’s MotionPower™ technology harvests, or captures, the “kinetic” or “motion” energy of cars, trucks, buses, and heavy commercial vehicles when they pass over the system or slow down before coming to a stop. MotionPower™ converts this captured energy into electricity. If successfully developed, MotionPower™ could potentially be used to harvest kinetic energy generated by any of the estimated 250 million vehicles registered in America (U.S. Department of Transportation Federal Highway Administration, 2008 Highway Statistics), which drive approximately six billion miles on our nation’s roadways every day (U.S. Environmental Protection Agency). The Company’s MotionPower™ technology is the subject of fifty-nine (59) patent filings.
	The Company’s product development programs involve ongoing research and development efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by its contract engineers, scientists, and consultants.
	The Company continues to assess the ongoing development and value propositions of its novel SolarWindow™ and MotionPower™ technologies. This assessment helps us strategically focus on specific technology development which best delivers significant long-term commercial competitive advantages.
Liquidity	'
	The Company is a development stage company, does not have any commercialized products and has not generated any revenue since inception. The Company has an accumulated deficit of $17,053,889 as of August 31, 2013, and does not have positive cash flows from operating activities. Included in the deficit are non cash expenses totaling $4,620,369 relating to the issuance of stock for services, compensatory stock options, warrants granted for value and accretion of debt discount. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.
	On February 1, 2013, the Company received $1,200,000 from an equity financing through the sale of its securities. As of August 31, 2013, the Company had cash and cash equivalents of $347,493. Subsequent to the Company’s fiscal year end, on October 7, 2013, the Company received proceeds of $3,000,000 in connection with issuing a 7% unsecured convertible note. Based upon its current and near term anticipated level of operations and expenditures, the Company believes that cash on hand should be sufficient to enable it to continue operations into our fiscal year ended August 31, 2015. However, there is no assurance that the Company will be able to generate revenue and achieve profitability or secure additional financing once the current cash balance is depleted.
	If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company’s business, operating results, financial condition and prospects. In particular, the Company may be required to delay, reduce the scope of or terminate one or more of its research programs, sell rights to its SolarWindow™ technology and/or MotionPowerTM technology or other technologies or products based upon such technologies, or license the rights to such technologies or products on terms that are less favorable to the Company than might otherwise be available.
Principles of Consolidation	'
	These consolidated financial statements presented are those of the Company and its wholly owned subsidiaries, Sungen, KEC, and New Energy Solar. All significant intercompany balances and transactions have been eliminated.
Estimates	'
	The preparation of the Company’s consolidated financial statements requires management to make estimates and use assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. On an on-going basis, the Company evaluates its estimates. Actual results and outcomes may differ materially from these estimates and assumptions.
Cash and Cash Equivalents	'
	Cash and cash equivalents includes highly liquid investments with original maturities of three months or less. The Company has amounts deposited with financial institutions in excess of federally insured limits.
Fair Value Measurement	'
	The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value:
	Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. The Company has no assets or liabilities valued with Level 1 inputs.
	Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. The Company has no assets or liabilities valued with Level 2 inputs.
	Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level 3 inputs.
Fair Value of Financial Instruments	'
	The carrying value of cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of our notes payable due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.
Research and Development	'
	Research and development costs represent costs incurred to develop the Company’s technology, including salaries and benefits for research and development personnel, allocated overhead and facility occupancy costs, supplies, equipment purchase and repair and other costs. Research and development costs are expensed when incurred, except for nonrefundable advance payments for future research and development activities which are capitalized and recognized as expense as the related services are performed.
Stock-Based Compensation	'
	The Company measures all employee stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes-Merton formula to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes-Merton formula requires management to make assumptions regarding the option lives, expected volatility, and risk free interest rates. See “Note 4 - Stockholders’ Equity (Deficit)” and “Note 5 - Stock Options” for additional information on the Company’s stock-based compensation plans.
Income Taxes	'
	The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.
Segment Reporting	'
	The Company’s business is considered to be operating in one segment based upon the Company’s organizational structure, the way in which the operations are managed and evaluated, the availability of separate financial results and materiality considerations.
Net Income (Loss) Per Share	'
	The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The computation of diluted net income per share does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on earnings per share. Therefore, when calculating EPS if the Company experienced a loss, there is no inclusion of dilutive securities as their inclusion in the EPS calculation is antidilutive. Furthermore, options and warrants will have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options or warrants (they are in the money). See “Note 6 - Net Loss Per Share” for further discussion.
	All share and per share amounts reflect the 1-for-3 reverse stock split declared effective on March 21, 2011, by FINRA.
Recently Adopted Accounting Pronouncements	'
	The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable to the Company, it has not identified any standards that it believes merit further discussion. The Company believes that none of the new standards will have a significant impact on its consolidated financial statements.

Stockholders_Equity_Deficit_Ta

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Aug. 31, 2013
Stockholders Equity Deficit Tables	'
Warrants outstanding and exercisable	'
	A summary of the Company’s warrants outstanding and exercisable as of August 31, 2013 and 2012 is as follows:
		Shares of Common Stock Issuable from Warrants Outstanding as of
	Description	31-Aug-13		31-Aug-12		Exercise Price		Expiration
	Series G		625,000		625,000	$	0.64	17-Apr-15
	Series H		1,755,126		-	$	0.83	1-Feb-16
	Total		2,380,126		625,000

Stock_Options_Tables

Stock Options (Tables)	12 Months Ended
	Aug. 31, 2013
Stock Options Tables	'
Stock option activity	'
	A summary of the Company’s stock option activity for the year ended August 31, 2013, and related information follows:
			Number of Options				Weighted Average Exercise Price ($)			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value ($)
	Outstanding at August 31, 2012			861,671				2.1
	Grants			177,500				1.59
	Exercises			(63,333	)			1.65
	Forfeitures			(5,000	)			3.27
	Outstanding at August 31, 2013			970,838				2.03		6.83 years		$	236,334
	Exercisable at August 31, 2013			479,337				2.42		6.27 years		$	108,084
	Available for grant at August 31, 2013			3,892,495
Share-based compensation cost	'
	The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Consolidated Statements of Operations for the years ended August 31, 2013 and 2012, and from May 5, 1998 (inception) to August 31, 2013:
			Year Ended August 31,								Cumulative
											5-May-98
											(Inception) to
											August 31,
			2013				2012				2013
	Stock Compensation Expense:
	Selling general and administrative expense		$	324,230			$	205,098			$	2,454,998
Stock options outstanding and exercisable	'
	The following table summarizes information about stock options outstanding and exercisable at August 31, 2013:
					Stock Options Outstanding										Stock Options Exercisable
	Range of				Number of				Weighted				Weighted		Number		Weighted Average		Weighted
	Exercise				Options				Average				Average		of Options		Remaining		Average
	Prices				Outstanding				Contractual				Exercise		Exercisable		Contractual		Exercise
									Life (years)				Price				Life (Years)		Price
	$	0.8				15,000				9.31			$	0.8		7,500		9.31	$	0.8
		1.32				50,001				1.29				1.32		50,001		1.29		1.32
		1.65				763,334				6.83				1.65		283,333		8.34		1.65
		2.3				2,500				8.66				2.3		2,500		8.66		2.3
		2.5				10,000				7.6				2.5		6,000		7.6		2.5
		2.55				33,334				5.03				2.55		33,334		5.03		2.55
		3.27				18,334				0.91				3.27		18,334		0.91		3.27
		4.98				16,667				4.53				4.98		16,667		4.53		4.98
		5.94				50,001				7.32				5.94		50,001		7.32		5.94
		6.51				11,667				1.08				6.51		11,667		1.08		6.51
	Total					970,838				6.83			$	2.03		479,337		6.27	$	2.42

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Aug. 31, 2013
Net Loss Per Share Tables	'
Computation of basic and diluted net loss per share	'
	Following is the computation of basic and diluted net loss per share for the years ended August 31, 2013 and 2012:
		Year Ended
		August 31,
		2013			2012
	Basic and Diluted EPS Computation
	Numerator:
	Loss available to common stockholders'	$	(4,272,532	)	$	(2,433,431	)
	Denominator:
	Weighted average number of common shares outstanding		22,686,892			20,638,360
	Basic and diluted EPS	$	(0.19	)	$	(0.12	)

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Aug. 31, 2013
Income Taxes Tables	'
Deferred tax assets	'
	Significant components of the Company’s deferred tax assets at August 31, 2013 and 2012 are as follows:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	3,404,418		$	2,506,712
	Capitalized research and development		836,568			756,562
	Depreciation		(4,700	)		(6,788	)
	Stock based compensation		1,130,104			659,793
	Research and development credit carry forward		206,715			174,558
	Total deferred tax assets		5,573,105			4,090,837
	Less: valuation allowance		(5,573,105	)		(4,090,837	)
	Net deferred tax asset	$	-		$	-
Income tax benefit	'
	The following is a reconciliation between expected income tax benefit and actual, using the applicable statutory income tax rate of 34% for the years ended August 31, 2013 and 2012:
		2013			2012
	Income tax benefit at statutory rate	$	1,452,661		$	827,367
	Non-deductible meals and entertainment		(2,550	)		(1,280	)
	Research and development credit		32,157			53,576
	Other		-			(10,330	)
	Change in valuation allowance		(1,482,268	)		(869,333	)

Organization_and_Going_Concern

Organization and Going Concern (Details Narrative) (USD $)	12 Months Ended
	Aug. 31, 2013
Organization And Going Concern Details Narrative	'
Accumulated deficit	$17,053,889
Cash and cash equivalents	347,493
Non cash expenses	$4,620,369

Accounts_Payable_Details_Narra

Accounts Payable (Details Narrative) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Accounts Payable Details Narrative	'	'
Accounts Payable	$122,356	$63,403
Accounts Payable Professional Service	42,539	24,863
Accounts Payable R&D	70,327	'
Accounts Payable Trade Payable	9,490	38,540
Accrued Liabilities	'	$26,231

Convertible_Promissory_Note_De

Convertible Promissory Note (Details Narrative) (USD $)	12 Months Ended		184 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Convertible Promissory Note Details Narrative	'	'	'
Interest expense related to the Loan	$999,485	'	'
Accretion related to the debt discount	515	'	'
Interest expense	$30,325	$26,231	$68,949

Stockholders_Equity_Deficit_De

Stockholders' Equity (Deficit) (Details) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Shares of Common Stock Issuable from Warrants	2,380,126	625,000
Series G [Member]	'	'
Shares of Common Stock Issuable from Warrants	625,000	625,000
Exercise Price	0.64	'
Expiration	17-Apr-15	'
Series H [Member]	'	'
Shares of Common Stock Issuable from Warrants	1,755,126	'
Exercise Price	0.83	'
Expiration	1-Feb-16	'

Stockholders_Equity_Deficit_De1

Stockholders' Equity (Deficit) (Details Narrative) (USD $)	12 Months Ended
	Aug. 31, 2013
Stockholders Equity Deficit Details Narrative	'
Series H warrants exercised	7,812
Cash received from excercised of series H warrants	$6,484

Stock_Options_Details

Stock Options (Details) (USD $)	12 Months Ended
	Aug. 31, 2013
Number of Options	'
Outstanding Beginning	861,671
Grants	177,500
Exercises	-63,333
Forfeitures	-5,000
Outstanding at August 31, 2013	970,838
Exercisable at August 31, 2013	479,337
Available for grant at August 31, 2013	3,892,495
Weighted Average Exercise Price ($)	'
Weighted-average exercise price	$2.10
Grants	$1.59
Exercises	$1.65
Forfeitures	$3.27
Weighted-average exercise price	$2.03
Exercisable at August 31, 2013	$2.42
Weighted Average Remaining Contractual Term	'
Outstanding at August 31, 2013	'6 years 9 months 29 days
Exercisable at August 31, 2013	'6 years 3 months 7 days
Aggregate Intrinsic Value ($)	'
Outstanding at August 31, 2013	$236,334
Exercisable at August 31, 2013	$108,084

Stock_Options_Details_1

Stock Options (Details 1) (USD $)	12 Months Ended						184 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2010	Aug. 31, 2009	Aug. 31, 2008	Aug. 31, 2013
Stock Compensation Expense:	'	'	'	'	'	'	'
Selling general and administrative expense	$324,230	$237,046	$2,855,630	$661,040	$183,312	$3,600,303	$7,871,637
Selling, General and Administrative Expenses [Member]	'	'	'	'	'	'	'
Stock Compensation Expense:	'	'	'	'	'	'	'
Selling general and administrative expense	'	'	'	'	'	'	2,405,499
Selling, General and Administrative Expenses [Member]	'	'	'	'	'	'	'
Stock Compensation Expense:	'	'	'	'	'	'	'
Selling general and administrative expense	'	$205,098	'	'	'	'	'

Stock_Options_Details_2

Stock Options (Details 2) (USD $)	12 Months Ended
	Aug. 31, 2013
Number of options outstanding	970,838
Weighted average contractural life (years)	'6 years 9 months 29 days
Weighted-average exercise price	$2.03
Number of options exercisable	479,337
Weighted average contractural life (years) of options exercisable	'6 years 3 months 7 days
Weighted-average exercise price of options exercisable	$2.42
$ 0.80 Per Share [Member]	'
Number of options outstanding	15,000
Weighted average contractural life (years)	'9 years 3 months 22 days
Weighted-average exercise price	$0.80
Number of options exercisable	7,500
Weighted average contractural life (years) of options exercisable	'9 years 3 months 22 days
Weighted-average exercise price of options exercisable	$0.80
$ 1.32 Per Share [Member]	'
Number of options outstanding	50,001
Weighted average contractural life (years)	'1 year 3 months 15 days
Weighted-average exercise price	$1.32
Number of options exercisable	50,001
Weighted average contractural life (years) of options exercisable	'1 year 3 months 15 days
Weighted-average exercise price of options exercisable	$1.32
$ 1.65 Per Share [Member]	'
Number of options outstanding	763,334
Weighted average contractural life (years)	'6 years 9 months 29 days
Weighted-average exercise price	$1.65
Number of options exercisable	283,333
Weighted average contractural life (years) of options exercisable	'8 years 4 months 2 days
Weighted-average exercise price of options exercisable	$1.65
$ 2.30 Per Share [Member]	'
Number of options outstanding	2,500
Weighted average contractural life (years)	'8 years 7 months 28 days
Weighted-average exercise price	$2.30
Number of options exercisable	2,500
Weighted average contractural life (years) of options exercisable	'8 years 7 months 28 days
Weighted-average exercise price of options exercisable	$2.30
$ 2.50 Per Share [Member]	'
Number of options outstanding	10,000
Weighted average contractural life (years)	'7 years 7 months 6 days
Weighted-average exercise price	$2.50
Number of options exercisable	6,000
Weighted average contractural life (years) of options exercisable	'7 years 7 months 6 days
Weighted-average exercise price of options exercisable	$2.50
$ 2.55 Per Share [Member]	'
Number of options outstanding	33,334
Weighted average contractural life (years)	'5 years 11 days
Weighted-average exercise price	$2.55
Number of options exercisable	33,334
Weighted average contractural life (years) of options exercisable	'5 years 11 days
Weighted-average exercise price of options exercisable	$2.55
$ 3.27 Per Share [Member]	'
Number of options outstanding	18,334
Weighted average contractural life (years)	'10 months 28 days
Weighted-average exercise price	$3.27
Number of options exercisable	18,334
Weighted average contractural life (years) of options exercisable	'10 months 28 days
Weighted-average exercise price of options exercisable	$3.27
$ 4.98 Per Share [Member]	'
Number of options outstanding	16,667
Weighted average contractural life (years)	'4 years 6 months 11 days
Weighted-average exercise price	$4.98
Number of options exercisable	16,667
Weighted average contractural life (years) of options exercisable	'4 years 6 months 11 days
Weighted-average exercise price of options exercisable	$4.98
$ 5.94 Per Share [Member]	'
Number of options outstanding	50,001
Weighted average contractural life (years)	'7 years 3 months 26 days
Weighted-average exercise price	$5.94
Number of options exercisable	50,001
Weighted average contractural life (years) of options exercisable	'7 years 3 months 26 days
Weighted-average exercise price of options exercisable	$5.94
$ 6.51 Per Share [Member]	'
Number of options outstanding	11,677
Weighted average contractural life (years)	'1 year 3 months 29 days
Weighted-average exercise price	$6.51
Number of options exercisable	11,667
Weighted average contractural life (years) of options exercisable	'1 year 3 months 29 days
Weighted-average exercise price of options exercisable	$6.51

Stock_Options_Details_Narrativ

Stock Options (Details Narrative) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Unrecognized compensation cost	$67,329	'
Expected period	'2 years	'
Amortization of the fair value of stock option	'	91,780
Stock based compensation reversed	'	23,705
Closing stock option exercise price	$1.90	'
Stock option outstanding	828,335	'
Stock bsed compensation expense	88,644	'
Stock bsed compensation recognized	'	66,252
Two Thousand Six Plan [Member]	'	'
Stock option grant shares	3,892,495	'
Stock option exercise	136,667	'
Javier Jimenez [Member]	'	'
Amortization of the fair value of stock option	'	66,252
Stock based compensation reversed	'	23,705
Stock option grant	'	68,075
On December 20, 2012 [Member]	'	'
Expense related to issuance	10,238	'
On January 23, 2013 [Member]	'	'
Expense related to issuance	225,349	'
On April 27, 2012 [Member]	'	'
Expense related to issuance	$5,625	'

Net_Loss_Per_Share_Details

Net Loss Per Share (Details) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Numerator:	'	'
Loss available to common stockholders	($4,272,532)	($2,433,431)
Denominator:	'	'
Weighted average number of common shares outstanding	22,686,892	20,638,360
Basic and diluted EPS	($0.19)	($0.12)

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Cash based Board compensation	$59,618	$91,200
Stock based compensation expense related to stock options granted non employee	176,699	90,297
Sierchio Company LLP [Member]	'	'
Legal services	128,924	176,404
Accounts payable	38,013	'
Mr Fusaro	'	'
Consulting fees	$2,100	$13,300

Income_Taxes_Details

Income Taxes (Details) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards	$3,404,418	$2,506,712
Capitalized research and development	836,568	756,562
Depreciation	-4,700	-6,788
Stock based compensation	1,130,104	659,793
Research and development credit carry forward	206,715	174,558
Total deferred tax assets	5,573,105	4,090,837
Less: valuation allowance	-5,573,105	-4,090,837
Net deferred tax asset	'	'

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Income Taxes Details 1	'	'
Income tax benefit at statutory rate	$1,452,661	$827,367
Non-deductible meals and entertainment	-2,550	-1,280
Research and development credit	32,157	53,576
Other	'	-10,330
Change in valuation allowance	-1,482,268	-869,333
Effective income tax	'	'

Income_Taxes_Details_Nerrative

Income Taxes (Details Nerrative) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Income Taxes Details Nerrative	'	'
net increase in the valuation allowance	$1,482,268	$869,333
Research and development credit carry forward	$206,715	$174,558